Add to a list

Inactive Instrument

Vivesto AB Share Price OTC Markets

OASMY

US67421W1099

Last Transcript: Vivesto AB

Vivesto AB - Special Call

24/11

More transcripts

Analysts' recommendations: Vivesto AB

26/05	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
21/11	DNB Carnegie Lowers Target Value for Vivesto Following Rights Issue Announcement	FW
13/25/13	DNB Carnegie Lowers Target Value for Vivesto as Costs Expected to Remain Steady	FW
09/24/09	Paccal Vet analysis could raise the temperature for Vivesto - Penser	FW
30/22/30	Orrön Energy the year's best and Isofol Medical the year's worst share on Nasdaq Stockholm	FW

More recommendations

News in other languages: Vivesto AB

25/20/25	Oasmia Pharmaceutical AB (publ) : un partenariat stratégique pour la distribution d'Apealea
30/20/30	Oasmia Pharmaceutical AB (publ) : Apealea arrive sur les marchés scandinaves

More news

Managers and Directors: Vivesto AB

Manager	Title	Age	Since
Erik Kinnman CEO	Chief Executive Officer	68	23/01/2023
Björn Svanström DFI	Director of Finance/CFO	55	01/07/2026
Teresa Fernandez Zafra CTO	Chief Tech/Sci/R&D Officer	39	01/01/2023

Director	Title	Age	Since
Isak Peter Zonabend CHM	Chairman	46	25/05/2022
Hege Hellstrom BRD	Director/Board Member	61	26/09/2019
Pål Ryfors BRD	Director/Board Member	43	25/05/2022

More insiders

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	9.52Cr 98.26L 86.09L 79.92L 73.44L 1.38Cr 95Cr 1.4Cr 3.73Cr 46Cr 3.69Cr 3.61Cr 160.27Cr	P/E 2026 *	-2.81x	P/E 2027 *	-2.05x
Enterprise Value	8.72Cr 90L 78.86L 73.21L 67.27L 1.27Cr 87Cr 1.29Cr 3.41Cr 42Cr 3.38Cr 3.31Cr 146.8Cr	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	56.4%	Yield 2026 *	-	Yield 2027 *	-

07/07	Vivesto chairman Peter Zonabend increases his shareholding	FW
01/07	Vivesto Completes Enrollment in Cat Study of Paccal Vet	FW
01/07	Vivesto Completes Recruitment in Paccal Vet Dose-Finding Study in Cats and Determines Maximum Tolerated Dose	CI
26/06	Vivesto Completes Enrollment in Canine Study	FW
26/06	Vivesto Completes Recruitment in Paccal Vet Dog Pilot Study	CI
17/06	Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study	CI
16/06	Vivesto reports positive results for intravenous Cantrixil	FW
05/06	Sweden's Vivesto Names New Finance Chief	MT
05/06	Vivesto appoints Björn Svanström as new CFO	FW
05/06	Vivesto AB Announces Chief Financial Officer Changes	CI
26/05	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
20/05	Vivesto trades on Nasdaq Stockholm today following 1:100 reverse stock split	FW
20/05	Calendar Wednesday May 20	FW

01/07	Vivesto: Cat study enrolment completed, results expected in Q4	AQ
01/07	Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose	AQ
26/06	Vivesto: Paccal Vet top-line results expected in Q3	AQ
26/06	Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026	AQ
16/06	Vivesto: Positive data for Cantrixil	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIVESTO AB	-.--%	-99.00%	-	-	98.26L
ELI LILLY AND COMPANY	-1.05%	+0.55%	+49.79%	+151.71%	1,03700Cr
JOHNSON & JOHNSON	+2.00%	+3.49%	+52.22%	+50.20%	62TCr
ABBVIE INC.	-1.09%	+3.76%	+35.37%	+76.22%	45TCr
ROCHE HOLDING AG	+2.26%	+2.93%	+30.62%	+24.79%	33TCr
NOVARTIS AG	-1.04%	+0.83%	+33.46%	+36.87%	29TCr
ASTRAZENECA PLC	-1.54%	-0.60%	+17.59%	+16.44%	26TCr
NOVO NORDISK A/S	-1.67%	-6.18%	-28.85%	-42.72%	22TCr
AMGEN INC.	-0.05%	+2.16%	+19.75%	+55.89%	20TCr
GILEAD SCIENCES, INC.	+0.05%	-1.03%	+18.31%	+61.63%	16TCr
Average	-0.29%	+1.12%	+25.36%	+47.89%	39.53TCr
Weighted average by Cap.	-0.45%	+1.47%	+35.04%	+72.34%

	2026 *	2027 *
Net sales	-	-
Net income	-3.1Cr -31.99L -28.03L -26.02L -23.91L -45.06L -31Cr -45.72L -1.21Cr -15Cr -1.2Cr -1.18Cr -52Cr	-4.6Cr -47.47L -41.59L -38.61L -35.48L -66.86L -46Cr -67.85L -1.8Cr -22Cr -1.78Cr -1.74Cr -77Cr
Net Debt	-80L -8L -7L -7L -6L -11.63L -7.97Cr -11.8L -31.31L -3.9Cr -30.99L -30.32L -13Cr	-1Cr -10.32L -9L -8L -8L -14.54L -9.96Cr -14.75L -39.14L -4.87Cr -38.74L -37.9L -17Cr

Vivesto AB Share Price OTC Markets

Stocks

OASMY

US67421W1099

Pharmaceuticals

Valuation: Vivesto AB

Chart: Vivesto AB

Latest news : Vivesto AB

Last Transcript: Vivesto AB

Analysts' recommendations: Vivesto AB

Press Releases: Vivesto AB

News in other languages: Vivesto AB

Managers and Directors: Vivesto AB

Other Pharmaceuticals

Financials

Company Profile